Computational chemistry company Evogene Ltd (NASDAQ: EVGN) (TASE: EVGN) announced on Wednesday that it has selected acute graft-versus-host disease (aGVHD) as the target indication for its internal AI-driven drug discovery programme, aiming to develop a potential first-in-class small-molecule treatment for patients who do not respond to steroids following stem cell transplantation.
The programme uses Evogene's proprietary ChemPass AI platform to design compounds targeting a biological pathway involved in severe inflammation. The company said it has generated a series of novel, potentially patentable candidates with nanomolar potency, target selectivity and favourable absorption, distribution, metabolism and excretion (ADME) and toxicology profiles, following exploration of a virtual chemical space of more than 110 billion molecules.
Development is guided by aGVHD specialists Dr Corey Cutler of Dana-Farber Cancer Institute and Professor Robert Zeiser of University Medical Center Freiburg, with the lead candidate series progressing towards investigational new drug (IND)-enabling studies.
Evogene cited the significant unmet medical need in aGVHD, which affects an estimated 30% - 40% of stem cell transplant recipients. Mortality among patients whose disease is resistant to steroid treatment can reach 50%, while ruxolitinib remains the only approved second-line therapy.
INOVIO prices public offering of approximately USD75m
First patient dosed in Phase 1 trial of Transgene and BioInvent's BT-001 for rectal cancer
Elicera Therapeutics secures Chinese patent allowance for ELC-401
CHOSA Oncology signs US laboratory agreement for Platin-DRP commercialisation
BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma
Pentixapharm advances preparationsfor Phase 3 PANDA study
CStone and Kimia Therapeutics collaborate to advance oncology drug candidate
Vivesto secures US orphan drug designation for Cantrixil in acute myeloid leukemia
Lytix Biopharma's ruxotemitide combination meets primary endpoint in Phase II melanoma trial
INOVIO's VOCERYQ receives US FDA accelerated approval to reduce surgery frequency in adults with RRP
Phrontline Biopharma reports preliminary safety and antitumour activity for TJ101
TME Pharma signs exclusive negotiation agreement with Japan's TMS for NOX-A12 rights
Evogene targets acute graft-versus-host disease for AI-driven drug discovery programme
Genmab reports 50% reduction in risk of death in Phase 3 head and neck cancer trial
Novocure and Verastem to evaluate combination therapy for pancreatic cancer